IN2012DN00570A - - Google Patents

Download PDF

Info

Publication number
IN2012DN00570A
IN2012DN00570A IN570DEN2012A IN2012DN00570A IN 2012DN00570 A IN2012DN00570 A IN 2012DN00570A IN 570DEN2012 A IN570DEN2012 A IN 570DEN2012A IN 2012DN00570 A IN2012DN00570 A IN 2012DN00570A
Authority
IN
India
Prior art keywords
biodegradable polymer
compositions
present
matrix
methods
Prior art date
Application number
Inventor
Noam Emanuel
Moshe Neuman
Shlomo Barak
Original Assignee
Polypid Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Polypid Ltd filed Critical Polypid Ltd
Publication of IN2012DN00570A publication Critical patent/IN2012DN00570A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
    • A61L24/001—Use of materials characterised by their function or physical properties
    • A61L24/0015—Medicaments; Biocides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/28—Materials for coating prostheses
    • A61L27/34—Macromolecular materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/08—Materials for coatings
    • A61L31/10—Macromolecular materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/22—Lipids, fatty acids, e.g. prostaglandins, oils, fats, waxes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
    • A61L2300/406—Antibiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/416—Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
    • A61L2300/602—Type of release, e.g. controlled, sustained, slow

Abstract

The present invention provides compositions for extended release of one or more active ingredients, comprising a lipid-saturated matrix formed from a non-biodegradable polymer or a block- co-polymers comprising a non-biodegradable polymer and a biodegradable polymer. The present invention also provides methods of producing the matrix compositions and methods for using the matrix compositions to provide controlled release of an active ingredient in the body of a subject in need thereof.
IN570DEN2012 2009-07-14 2010-07-14 IN2012DN00570A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22528909P 2009-07-14 2009-07-14
PCT/IL2010/000563 WO2011007353A1 (en) 2009-07-14 2010-07-14 Sustained-release drug carrier composition

Publications (1)

Publication Number Publication Date
IN2012DN00570A true IN2012DN00570A (en) 2015-06-12

Family

ID=43448999

Family Applications (1)

Application Number Title Priority Date Filing Date
IN570DEN2012 IN2012DN00570A (en) 2009-07-14 2010-07-14

Country Status (9)

Country Link
US (2) US8992979B2 (en)
EP (1) EP2453877B1 (en)
JP (1) JP5738856B2 (en)
CN (2) CN105126179B (en)
AU (1) AU2010272167B2 (en)
CA (1) CA2767973C (en)
ES (1) ES2732149T3 (en)
IN (1) IN2012DN00570A (en)
WO (1) WO2011007353A1 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2630805T3 (en) 2008-07-14 2017-08-24 Polypid Ltd. Sustained release drug vehicle composition
US8795726B2 (en) 2010-01-19 2014-08-05 Polypid Ltd. Sustained-release nucleic acid matrix compositions
EP2736492A4 (en) * 2011-07-27 2015-06-17 Polypid Ltd Matrix compositions for controlled release of peptide and polypeptide molecules
JP5900909B2 (en) * 2012-03-27 2016-04-06 国立大学法人名古屋大学 Three-dimensional structure made from material containing polyhydroxyalkanoate and kit for preparing bone filler
US9173976B2 (en) * 2012-08-02 2015-11-03 Polypid Ltd. Compositions and methods for the treatment of bone voids and open fractures
CA2885334C (en) * 2012-11-14 2016-03-08 Orthopaedic Innovation Centre Inc. Antimicrobial articles produced by additive manufacturing
US9775853B2 (en) 2013-03-15 2017-10-03 Biomet Manufacturing, Llc. Hemostatic compositions and methods
TW201618783A (en) 2014-08-07 2016-06-01 艾森塔製藥公司 Methods of treating cancers, immune and autoimmune diseases, and inflammatory diseases based on BTK occupancy and BTK resynthesis rate
JP6526400B2 (en) * 2014-09-11 2019-06-05 サンスター株式会社 Oral composition
JP2017531461A (en) * 2014-10-02 2017-10-26 ポリピッド リミテッド Treatment of peri-implantitis
EA201790383A1 (en) * 2014-10-02 2017-09-29 Полипид Лтд. COMPOSITIONS AND METHODS OF TREATMENT AND PREVENTION OF INFECTIONS OF SURGERY INTERVENTION
WO2017139357A1 (en) * 2016-02-08 2017-08-17 Orbusneich Medical, Inc. Drug eluting balloon
US10792477B2 (en) 2016-02-08 2020-10-06 Orbusneich Medical Pte. Ltd. Drug eluting balloon
CN106146761A (en) * 2016-06-03 2016-11-23 西北大学 The nano-micelle of a kind of amphipathic multifunctional polymer and preparation thereof and application
JP7102423B2 (en) * 2017-02-16 2022-07-19 イェダ リサーチ アンド ディベロップメント カンパニー リミテッド Liposomal drug delivery vehicle
US11690807B2 (en) 2018-05-24 2023-07-04 Celanese Eva Performance Polymers Llc Implantable device for sustained release of a macromolecular drug compound
SG11202005949UA (en) 2018-05-24 2020-07-29 Celanese Eva Performance Polymers Corp Implantable device for sustained release of a macromolecular drug compound
CN113081482B (en) * 2021-04-23 2024-02-27 柏为（武汉）医疗科技股份有限公司 Middle ear anti-adhesion membrane and preparation method thereof
CN113702647B (en) * 2021-08-31 2024-03-15 普十生物科技(北京)有限公司 Human growth differentiation factor 15 instant detection kit, preparation method and application thereof

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4522803A (en) 1983-02-04 1985-06-11 The Liposome Company, Inc. Stable plurilamellar vesicles, their preparation and use
US4882167A (en) 1983-05-31 1989-11-21 Jang Choong Gook Dry direct compression compositions for controlled release dosage forms
US4578384A (en) 1984-02-15 1986-03-25 The United States Of America As Represented By The Secretary Of The Army Polylactic-polyglycolic acids combined with an acidic phospholipid-lysozyme complex for healing osseous tissue
JPS6163613A (en) 1984-09-04 1986-04-01 Mitsui Toatsu Chem Inc Sustained release preparation
US5043166A (en) 1987-01-09 1991-08-27 Hadasit Medical Research, Inc. Liposome/anthraquinone drug composition and method
IL91664A (en) 1988-09-28 1993-05-13 Yissum Res Dev Co Ammonium transmembrane gradient system for efficient loading of liposomes with amphipathic drugs and their controlled release
ES2085465T3 (en) 1989-11-13 1996-06-01 Abraham J Domb LIPOESFERAS FOR THE CONTROLLED ADMINISTRATION OF SUBSTANCES.
US6120805A (en) 1990-04-06 2000-09-19 Rhone-Poulenc Rorer Sa Microspheres, process for their preparation and their use
US5922340A (en) 1992-09-10 1999-07-13 Children's Medical Center Corporation High load formulations and methods for providing prolonged local anesthesia
US6180134B1 (en) 1993-03-23 2001-01-30 Sequus Pharmaceuticals, Inc. Enhanced ciruclation effector composition and method
CA2190121A1 (en) 1994-03-15 1995-09-21 Edith Mathiowitz Polymeric gene delivery system
US6156337A (en) 1994-07-08 2000-12-05 Opperbas Holding B.V. Method for high loading of vesicles with biopolymeric substances
US6333021B1 (en) 1994-11-22 2001-12-25 Bracco Research S.A. Microcapsules, method of making and their use
US6040295A (en) 1995-01-13 2000-03-21 Genemedicine, Inc. Formulated nucleic acid compositions and methods of administering the same for gene therapy
US5919480A (en) 1996-06-24 1999-07-06 Yissum Research Development Company Of The Hebrew University Of Jerusalem Liposomal influenza vaccine composition and method
US5837221A (en) 1996-07-29 1998-11-17 Acusphere, Inc. Polymer-lipid microencapsulated gases for use as imaging agents
WO1998007412A1 (en) 1996-08-21 1998-02-26 Alkermes Controlled Therapeutics, Inc. Controlled release microparticles with a hydrophobic material
DE69737915T2 (en) 1996-09-11 2008-03-13 Bristol-Myers Squibb Medical Imaging, Inc. Method of diagnostic imaging of the kidney region using a contrast agent and a vasodilator
US6048551A (en) 1997-03-27 2000-04-11 Hilfinger; John M. Microsphere encapsulation of gene transfer vectors
IL129951A0 (en) 1997-07-02 2000-02-29 Euro Celtique Sa Prolonged anesthesia in joints and body spaces
US6287587B2 (en) 1997-07-15 2001-09-11 Takeda Chemical Industries, Ltd. Process for producing sustained-release preparation by in-water drying
US6787132B1 (en) 1997-12-04 2004-09-07 Yissum Research Development Company Of The Hebrew University Of Jerusalem Combined chemo-immunotherapy with liposomal drugs and cytokines
CA2329768C (en) 1998-04-27 2008-06-10 Opperbas Holding B.V. Pharmaceutical composition comprising factor viii and neutral liposomes
US6423345B2 (en) 1998-04-30 2002-07-23 Acusphere, Inc. Matrices formed of polymer and hydrophobic compounds for use in drug delivery
ATE428371T1 (en) 1998-07-17 2009-05-15 Pacira Pharmaceuticals Inc BIODEGRADABLE ARRANGEMENTS FOR THE CONTROLLED RELEASE OF ENCLOSED SUBSTANCES
CA2340118C (en) 1998-08-12 2009-01-13 Yissum Research Development Company Of The Hebrew University Of Jerusalem Liposomal bupivacaine compositions prepared using an ammonium sulfate gradient
US6153217A (en) 1999-01-22 2000-11-28 Biodelivery Sciences, Inc. Nanocochleate formulations, process of preparation and method of delivery of pharmaceutical agents
US6083482A (en) 1999-05-11 2000-07-04 Icn Pharmaceuticals, Inc. Conformationally locked nucleosides and oligonucleotides
AU5624400A (en) 1999-06-18 2001-01-09 Collaborative Group, Ltd., The Hyaluronic acid film and matrix for sustained gene transfer
DE10001172A1 (en) 2000-01-13 2001-07-26 Max Planck Gesellschaft Templating solid particles with polymer multilayers
US6967028B2 (en) 2000-07-31 2005-11-22 Mainelab Prolonged release microspheres for injectable administration
US20030161809A1 (en) * 2000-10-02 2003-08-28 Houston L. L. Compositions and methods for the transport of biologically active agents across cellular barriers
FI20010540A0 (en) 2001-03-16 2001-03-16 Yli Urpo Antti Composite for the correction of defects in soft and hard tissue and the use of said composite
MXPA04002980A (en) * 2001-09-28 2005-06-20 Johnson & Johnson Dosage forms having an inner core and outer shell with different shapes.
TWI226249B (en) 2001-12-19 2005-01-11 Ind Tech Res Inst Biodegradable composite matrix for enhancing angiogenesis
EP3100719A3 (en) 2002-05-15 2017-02-22 California Pacific Medical Center Delivery of nucleic acid-like compounds
US20040062778A1 (en) * 2002-09-26 2004-04-01 Adi Shefer Surface dissolution and/or bulk erosion controlled release compositions and devices
TWI367113B (en) * 2003-02-12 2012-07-01 Syncera Inc Random and non-random alkylene oxide polymer alloy compositions
GB0305941D0 (en) 2003-03-14 2003-04-23 Camurus Ab Composition
CA2521916C (en) 2003-04-10 2013-06-25 Teijin Limited Biodegradable film having a honeycomb structure for the prevention of postoperative tissue adhesion
US20040247624A1 (en) * 2003-06-05 2004-12-09 Unger Evan Charles Methods of making pharmaceutical formulations for the delivery of drugs having low aqueous solubility
US20060188573A1 (en) * 2003-06-10 2006-08-24 Anna Imberg Composite materials and particles
US20050249697A1 (en) 2003-09-24 2005-11-10 Uhrich Kathryn E Compositions and methods for the inhibition of bone growth and resorption
EP1693075B1 (en) 2003-11-21 2012-10-03 Teijin Limited Substrate for tissue regeneration
CA2553426A1 (en) 2004-01-15 2005-08-04 Alza Corporation Liposome composition for delivery of therapeutic agents
US8277831B2 (en) * 2004-02-17 2012-10-02 Advanced Technologies And Regenerative Medicine, Llc. Drug-enhanced adhesion prevention
US7744644B2 (en) 2004-03-19 2010-06-29 Boston Scientific Scimed, Inc. Medical articles having regions with polyelectrolyte multilayer coatings for regulating drug release
DE102004025495A1 (en) * 2004-05-21 2005-12-15 Dr. Suwelack Skin & Health Care Ag Process for the production of alginate-containing porous moldings
NZ551990A (en) 2004-06-04 2011-01-28 Camurus Ab Liquid depot formulations
US20050287180A1 (en) * 2004-06-15 2005-12-29 Chen Andrew X Phospholipid compositions and methods for their preparation and use
US7906140B2 (en) 2004-06-17 2011-03-15 Virun, Inc. Compositions for mucosal delivery of agents
KR20070054644A (en) 2004-07-26 2007-05-29 액테리온 파마슈티칼 리미티드 Treatment of pulmonary hypertension by inhaled iloprost with a microparticle formulation
US8790672B2 (en) * 2005-02-22 2014-07-29 Nina M. Lamba-Kohli Generation of antimicrobial surfaces using dendrimer biocides
JP2008539260A (en) 2005-04-25 2008-11-13 アムジエン・インコーポレーテツド Biodegradable ptide sustained-release composition containing porogen
US20070141134A1 (en) 2005-12-16 2007-06-21 Kosak Matthew K Shielded micelles for polynucleotide delivery
US20090318355A1 (en) 2006-02-15 2009-12-24 Chen Thomas T Compositions and methods for promoting tissue repair and wound healing
ES2776100T3 (en) 2006-03-31 2020-07-29 Massachusetts Inst Technology System for targeted delivery of therapeutic agents
US8703167B2 (en) * 2006-06-05 2014-04-22 Advanced Cardiovascular Systems, Inc. Coatings for implantable medical devices for controlled release of a hydrophilic drug and a hydrophobic drug
CA2656179A1 (en) * 2006-06-21 2007-12-27 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for joining non-conjoined lumens
CN101209243B (en) * 2006-12-29 2010-12-08 石药集团中奇制药技术（石家庄）有限公司 Liposome medicament and preparation thereof
RU2428186C2 (en) * 2007-03-02 2011-09-10 Теика Фармасьютикал Ко., Лтд. Medical composition for percutaneous absorbtion, product keeping medical composition, and preparation for percutaneous absorbtion containing it
WO2008124634A1 (en) 2007-04-04 2008-10-16 Massachusetts Institute Of Technology Polymer-encapsulated reverse micelles
WO2009006311A2 (en) 2007-06-29 2009-01-08 Wisconsin Alumni Research Foundation Structuring effect of cholesterol in peg-phospholipid micelles, drug delivery of amphotericin b, and combination antifungals
US20090110713A1 (en) 2007-10-31 2009-04-30 Florencia Lim Biodegradable polymeric materials providing controlled release of hydrophobic drugs from implantable devices
AU2008325122A1 (en) 2007-11-09 2009-05-14 Northeastern University Self-assembling micelle-like nanoparticles for systemic gene delivery
WO2009110939A2 (en) 2007-12-10 2009-09-11 Massachusetts Institute Of Technology Drug delivery system for pharmaceuticals and radiation
US8128983B2 (en) 2008-04-11 2012-03-06 Abbott Cardiovascular Systems Inc. Coating comprising poly(ethylene glycol)-poly(lactide-glycolide-caprolactone) interpenetrating network
AU2009238175C1 (en) 2008-04-15 2023-11-30 Arbutus Biopharma Corporation Novel lipid formulations for nucleic acid delivery
ES2630805T3 (en) 2008-07-14 2017-08-24 Polypid Ltd. Sustained release drug vehicle composition
US9012622B2 (en) 2008-12-31 2015-04-21 Patrick Y. Lu Compositions and methods using siRNA molecules and siRNA cocktails for the treatment of breast cancer
CN102985548B (en) 2009-05-16 2016-10-26 崔坤元 For deliver treatment molecule comprise cationic amphiphilic thing and the compositions of auxiliary lipid
US8795726B2 (en) 2010-01-19 2014-08-05 Polypid Ltd. Sustained-release nucleic acid matrix compositions
CA2861848A1 (en) * 2012-01-10 2013-06-28 Monika Mujkic Renewable fatty acid waxes and methods of making

Also Published As

Publication number Publication date
US8992979B2 (en) 2015-03-31
JP2012533334A (en) 2012-12-27
US20150174073A1 (en) 2015-06-25
US20120114756A1 (en) 2012-05-10
US10463617B2 (en) 2019-11-05
WO2011007353A1 (en) 2011-01-20
CA2767973A1 (en) 2011-01-20
JP5738856B2 (en) 2015-06-24
EP2453877A4 (en) 2013-05-29
CN102470105A (en) 2012-05-23
CN105126179A (en) 2015-12-09
AU2010272167A1 (en) 2012-02-02
CN102470105B (en) 2015-07-29
ES2732149T3 (en) 2019-11-20
EP2453877A1 (en) 2012-05-23
CN105126179B (en) 2018-09-25
AU2010272167B2 (en) 2016-11-17
CA2767973C (en) 2019-06-18
EP2453877B1 (en) 2019-05-08

Similar Documents

Publication Publication Date Title
IN2012DN00570A (en)
PH12021550756A1 (en) Compositions and methods for treating and/or preventing cardiovascular disease
MX2010003299A (en) Micromirs.
BRPI0917017B8 (en) s-nitrosoglutathione reductase pyrrole inhibitors as therapeutic agents
IL211541A0 (en) Co-crystal compositions, methods of producing the same and uses thereof
GB2488075B (en) Polymer composition, swellable composition comprising the polymer composition, and articles including the swellable composition
ZA201008398B (en) An electrochemically active composition,methods of making,and uses thereof
EP2305209A3 (en) Composition comprising a polyol,a sugar silicone surfactant and an oil-soluble high carbon polar modified polymer
EP2569330A4 (en) Chlorotoxin variants, conjugates, and methods for their use
WO2010017215A3 (en) Biodegradable microspheres and methods of use thereof
WO2010125475A3 (en) Sustained release formulations comprising gnrh analogues
PL2513023T3 (en) Compositions and uses of cis-1,1,1,4,4,4-hexafluoro-2-butene
WO2008087215A3 (en) Partially bioabsorbable implant
WO2011003902A3 (en) Multimodal visible polymer embolization material
EP2488023A4 (en) Antimicrobial composition
EP2395048A3 (en) Polymers compositions including an antioxidant
BRPI1011188A2 (en) dermal release compositions comprising calcium phosphate-active agent particle complexes and methods for using them.
MX2011012504A (en) Pyrazinylpyrazoles.
UA86731C2 (en) Divisible galenic form of the modified drug release
UA103025C2 (en) Solid pharmaceutical formulation with delayed release
MX2012007365A (en) Slow release pharmaceutical compositions of iloperidone.
IN2012DN03404A (en)
WO2011035013A3 (en) Implant devices that differ by release profile and methods of making and using same
MX2011006721A (en) Pharmaceutical formulation of nanonised fenofibrate.
MX2014006574A (en) Acamprosate formulations, methods of using the same, and combinations comprising the same.